Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome

NCT: NCT07568860 · NOT_YET_RECRUITING

NCT IDNCT07568860
StatusNOT_YET_RECRUITING
Start Date2026-10-01
Completion2031-09-30

Brief Summary

The goal of this clinical trial is to explore a new type of personalized brain stimulation that works during day time and night time hours using the Medtronic Percept Deep Brain Stimulation (DBS) device in patients with Lennox-Gastaut Syndrome. The main question(s) this study aims to answer is: 1. Does using the personalized DBS reduce motor seizures compared to conventional DBS? 2. Is the number of seizures reported by caregivers different for patients using the personalized DBS? 3. How often do patients using the personalized DBS experience undesired side effects? Researchers will compare the personalized DBS that works night time, personalized DBS device that works during the day time, and conventional DBS. Participants will: 1. Have their seizures and sleep patterns recorded for 3-months 2. Assess their neurocognitive function 3. Answer questionnaires about communication, movement, and sleep quality 4. Wear a sleep headband and seizure warning watch for 5 nights 5. Complete a mood and sleep assessment 6. Have a 3T and possibly 7T MRI 7. Be implanted with stereo-encephalography and undergo 3\~5 days of monitoring 8. Have the stereo-encephalography taken out 9. Receive DBS implantation through surgery and have several months of stimulation and no stimulation periods 10. Have routine clinical visits to check on healing after surgery 11. Have their caregiver help them keep a dairy about their seizures, sleep and quality of life

Frequently Asked Questions

What is Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome?

Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome is a clinical trial registered under NCT07568860. Current status: NOT_YET_RECRUITING.

What is the status of NCT07568860?

The current status of NCT07568860 (Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome) is: NOT_YET_RECRUITING.

When did Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome start?

Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome started on 2026-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.